Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.100
-0.025 (-0.80%)
At close: Aug 5, 2026, 4:00 PM EDT
3.030
-0.070 (-2.26%)
After-hours: Aug 5, 2026, 7:34 PM EDT
Voyager Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Voyager Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $14.89. The average 1-year stock price forecast is 380.32% higher than the current stock price, while the lowest is $8.00 (+158.06%) and the highest is $25 (+706.45%).
Price Target: $14.89 (+380.32%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Voyager Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 11 | 11 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +706.45% | Jul 20, 2026 |
| Wedbush | Wedbush | Buy Maintains $8 | Buy | Maintains | $8 | +158.06% | Jul 14, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $12 | Buy | Reiterates | $12 | +287.10% | Jul 14, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 14, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $22 | Buy | Maintains | $22 | +609.68% | Jun 2, 2026 |
Financial Forecast
Revenue This Year
39.27M
from 40.37M
Decreased by -2.73%
Revenue Next Year
57.22M
from 39.27M
Increased by 45.69%
EPS This Year
-1.66
from -2.04
EPS Next Year
-1.56
from -1.66
EPS and Forward PE are based on non-GAAP adjusted numbers.